XAIR On March 24, NeuroNOS secured $2 million for an autism drug using nitric oxide (NO), showing strong preclinical results. March 31 brought a Vanderbilt partnership for LungFit PH, a tankless NO system to boost hospital sales. On April 1, NeuroNOS linked NO to Alzheimer’s, targeting a $1 trillion market. On April 9, a pilot study proved LungFit GO’s safety for at-home NTM treatment. Up 4.8% from $0.229 on April 4, XAIR has huge potential in lung and brain disease innovation.
